Analyzing Pharma Bio Serv (PBSV) & Its Rivals

Pharma Bio Serv (OTCMKTS: PBSV) is one of 26 publicly-traded companies in the “Management consulting services” industry, but how does it compare to its competitors? We will compare Pharma Bio Serv to similar companies based on the strength of its institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

Analyst Recommendations

This is a summary of current ratings for Pharma Bio Serv and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pharma Bio Serv 0 0 0 0 N/A
Pharma Bio Serv Competitors 124 409 582 30 2.45

As a group, “Management consulting services” companies have a potential upside of 12.05%. Given Pharma Bio Serv’s competitors higher probable upside, analysts plainly believe Pharma Bio Serv has less favorable growth aspects than its competitors.

Institutional & Insider Ownership

65.2% of shares of all “Management consulting services” companies are owned by institutional investors. 51.6% of Pharma Bio Serv shares are owned by company insiders. Comparatively, 10.6% of shares of all “Management consulting services” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Dividends

Pharma Bio Serv pays an annual dividend of $0.08 per share and has a dividend yield of 6.7%. Pharma Bio Serv pays out -133.3% of its earnings in the form of a dividend. As a group, “Management consulting services” companies pay a dividend yield of 1.5% and pay out 35.4% of their earnings in the form of a dividend. Pharma Bio Serv is clearly a better dividend stock than its competitors, given its higher yield and lower payout ratio.

Earnings & Valuation

This table compares Pharma Bio Serv and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Pharma Bio Serv $15.58 million -$1.41 million -19.83
Pharma Bio Serv Competitors $993.84 million $66.10 million 20.66

Pharma Bio Serv’s competitors have higher revenue and earnings than Pharma Bio Serv. Pharma Bio Serv is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Pharma Bio Serv and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pharma Bio Serv -14.93% 0.49% 0.41%
Pharma Bio Serv Competitors -16.11% -37.32% -2.66%

Risk and Volatility

Pharma Bio Serv has a beta of 0.13, indicating that its stock price is 87% less volatile than the S&P 500. Comparatively, Pharma Bio Serv’s competitors have a beta of 0.80, indicating that their average stock price is 20% less volatile than the S&P 500.

About Pharma Bio Serv

Pharma-Bio Serv, Inc. operates as a compliance and technology transfer services consulting firm with a laboratory testing facility in Puerto Rico, the United States, Europe, and Brazil markets. It provides compliance consulting services to the pharmaceutical, chemical, biotechnology, medical device, cosmetic, food industries, and allied products in Puerto Rico, the United States, Europe, and Brazil. The company's technical consulting services comprise regulatory compliance, validation, technology transfer, engineering, project management, and process support. It also offers microbiological and chemical testing services through its lab; and technical trainings/seminars. The company markets its services through industry trade shows, professional conventions, industry publications, and seminars. Pharma-Bio Serv, Inc. was founded in 1993 and is headquartered in Dorado, Puerto Rico.

Receive News & Ratings for Pharma Bio Serv Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharma Bio Serv and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply